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ARL2 is a member of the ADP-ribosylation factor
family but has unique biochemical features. BART
is an effector of ARL2 that is essential for nuclear
retention of STAT3 and may also be involved in mito-
chondria transport and apoptosis. Herewe report the
crystal structure and biochemical characterization
of human ARL2-GTP-BART complex. ARL2-GTP
assumes a typical small GTPase fold with a unique
N-terminal a helix conformation. BART consists of
a six a helix bundle. The interactions between ARL2
and BART involve two interfaces: a conserved
N-terminal LLXIL motif of ARL2 is embedded in
a hydrophobic cleft of BART and the switch regions
of ARL2 interact with helix a3 of BART. Both inter-
faces are essential for the binding as verified by
mutagenesis study. This novel recognition and
binding mode is different from that of other small
GTPase-effector interactions and provides molec-
ular basis for the high specificity of ARL2 for BART.
INTRODUCTION
The ADP-ribosylation factor (ARF) family of the RAS superfamily
is constituted by the ARF, SAR, and ARF-like (ARL) proteins
(Kahn et al., 2006; Li et al., 2004; Pasqualato et al., 2002). The
extensively studied ARF proteins are characteristic with the
presence of an N-terminal a helix that can be myristoylated for
interaction with membrane lipids and are well known for their
roles in the regulation of vesicle formation in intracellular traf-
ficking (Donaldson and Jackson, 2000; Kahn et al., 2006; Nie
et al., 2003). The SAR proteins are nonmyristoylated but share
some functional relatedness to the ARF proteins in that they
can target to membrane and initiate vesicle budding through
interaction of their N-terminal a helix with integral membrane
proteins (Bi et al., 2002; Huang et al., 2001; Kuge et al., 1994;
Nakano and Muramatsu, 1989). Although the exact biological
functions of the ARL proteins are largely unknown, the limited
knowledge to date has revealed thegreat diversity of theseproteins
(reviewed in Burd et al. [2004]). ARL1 is an atypical ARL protein
and shares some characteristic features of the ARF proteins. It602 Structure 17, 602–610, April 15, 2009 ª2009 Elsevier Ltd All righis membrane associated and involved in vesicle trafficking and
actin remodeling (Amor et al., 2001; Panic et al., 2003a, 2003b;
Wu et al., 2004). The closely related ARL2 and ARL3, which share
54% sequence identity, have unique biochemical and structural
features that distinguish them from the ARF proteins (Hillig et al.,
2000; Hanzal-Bayer et al., 2002). ARL2 and ARL3 are nonmyris-
toylated despite the presence of a myristoylation site at the
N terminus (Gly2) and are unable to activate phospholipase D,
both of which are characteristic features of the ARF proteins
(Hong et al., 1998; Sharer et al., 2002). On the other hand, the
N-terminal Met of ARL3 is acetylated and the acetylation is
required for its targeting to the Golgi through interaction with
the membrane protein SYS1P (Behnia et al., 2004; Setty et al.,
2004). The N-terminal region of ARL3 folds into an elongated
loop that is hydrophobically anchored onto the surface in the
structure of ARL3-GDP and is predicted to be released upon
the GTP binding (Hillig et al., 2000). The N-terminal region of
ARL2 folds into an a helix that is solvent exposed in the structure
of ARL2-GTP in complex with its effector PDEd (Hanzal-Bayer
et al., 2002). Nevertheless, the inter-switch regions of both
ARL2 and ARL3 undergo a b sheet register shift similar to that
of the ARF proteins during the GDP-GTP exchange. These
data suggest that ARL2 and ARL3 might have distinct biological
functions. Indeed, a body of biochemical and genetic evidence
has shown that both ARL2 and ARL3 play important roles in
microtubule biogenesis although they regulate different microtu-
bule-dependent processes (Antoshechkin and Han, 2002; Bha-
midipati et al., 2000; Radcliffe et al., 2000; Shern et al., 2003;
Zhou et al., 2006). The ortholog of ARL2 inSchizosaccharomyces
pombe (ALP41) is essential for normal microtubule function and
growth polarity (Radcliffe et al., 2000). The Caenorhabditis ele-
gans homolog of ARL2 (EVL20) can regulate microtubule
dynamics during cytokinesis andmorphogenesis and is required
for embryogenesis (Antoshechkin and Han, 2002). In human
cells, knockdown of ARL3 leads to abnormal cell morphology
and failure in cytokinesis, whereas overexpression of a
GTPase-defective ARL2mutant (Q70L) results in loss of microtu-
bules and a G2/M arrest (Zhou et al., 2006).
Small GTPases, which act as molecular switches cycling
between the inactive GDP-bound state and the active GTP-
bound state, are regulated by guanosine nucleotide exchange
factors and GTPase-activating proteins (GAPs) and exert diver-
sified functions through interactions with various effectors. To
date, several putative effectors have been identified for ARL2ts reserved
Structure
Crystal Structure of Human ARL2-GTP-BART Complexand ARL3. In mammalian cells, ARL2 but not ARL3 is associated
with a tubulin folding chaperon, namely cofactor D (Bhamidipati
et al., 2000; Shern et al., 2003). Intriguingly, it is the GDP-bound
but not the GTP-bound ARL2 interacting with cofactor D that is
unique for small GTPases. The putative effectors for both
Table 1. Summary of Diffraction Data and Structure Refinement
Statistics
Form I Form II
Data collection
Wavelength (A˚) 1.5596 1.0000
Space group P21 P212121
Resolution (A˚) 50.00–2.25
(2.33–2.25)a
50.00–3.30
(3.42–3.30)
Cell parameters
a, b, c (A˚) 57.83, 44.08,
66.50
44.66, 45.17,
175.88
b () 111.46 90.00
Observed reflections 96,833 (5,634) 30,918 (2,995)
Unique reflections (I/s(I) > 0) 14,727 (1,252) 5,818 (565)
Average redundancy 6.6 (4.5) 5.3 (5.3)
Average I/s(I) 27.9 (4.0) 11.4 (2.4)
Completeness (%) 97.7 (83.7) 99.4 (97.3)
Rmerge (%) 6.5 (21.6) 16.1 (75.9)
Refinement
Resolution (A˚) 50.00–2.25 50.00–3.30
Reflections (FoR 0s(Fo))
Working set/test set 13,233/742 5,520/297
Rwork/Rfree 0.230/0.261 0.253/0.294
Number of protein atoms 2,485 2,526
Number of GTP atoms 33 33
Number of Mg2+ atom 1 1
Number of water atoms 106 15
Average B factor
of all atoms (A˚2)
38.0 74.5
ARL2 main
chain/side chain
31.5/34.1 68.8/70.1
BART main
chain/side chain
45.5/46.4 87.9/87.0
GTP 27.2 70.4
Mg2+ 28.9 39.9
Water 38.5 34.1
RMS deviation
Bond lengths (A˚) 0.008 0.007
Bond angles () 1.3 1.4
Ramachandran plot (%)b
Favored 96.0 89.2
Allowed 100.0 100.0
Outliers 0 0
Luzzati atomic
positional error (A˚)
0.30 0.75
aNumbers in parentheses represent the highest resolution shell.
b Statistics of the Ramachandran plot was analyzed using MolProbity.Structure 17ARL2-GTP and ARL3-GTP include binder of ARL2 (BART)
(Sharer and Kahn, 1999), human retinal gene 4 (Kobayashi
et al., 2003), and the d subunit of rod-specific cGMP phosphodi-
esterase type 6 (PDEd) (Linari et al., 1999). Retinitis pigmentosa
2 is a GAP for ARL3 (Veltel et al., 2008). ELMOD2 is another puta-
tive GAP for the ARL proteins that exhibits high GAP activity for
ARL2 and minor GAP activity for ARL3, ARL6, and the ARF
proteins (Bowzard et al., 2007).
BART is the first identified effector of ARL2 that has a high
affinity for ARL2-GTP (apparent KD of 20 nM) (Sharer and
Kahn, 1999). It is most abundant in brain, especially in hippo-
campus and cortex, but can also be expressed in heart, lung,
liver, and kidney (Sharer and Kahn, 1999; Sharer et al., 2002).
The expression level of BART in epithelial cells is normally low;
however, about a 3.4-fold protein increase was observed in
a head and neck cancer cell line during hypoxia (Chen et al.,
2004). The subcellular localization of BART seems to be diver-
gent in various cell lines. In glioblastoma SF295 cells, most of
BART and ARL2 proteins are present in the cytosol, whereas
about 10%–20% of both proteins are localized to the intermem-
brane space of mitochondria where BART can bind an ADP/ATP
transporter, namely adenine nucleotide translocase 1 (ANT1),
suggesting a functional role of BART and ARL2 in mitochondria
transport and/or apoptosis (Sharer and Kahn, 1999; Sharer
et al., 2002). BART is also shown to be colocalized with ARL3
to midbodies and seems to function during mitosis (Zhou et al.,
2006). Recently, BART was observed in the nucleus and was
shown to be essential for nuclear retention of signal transducers
and activators of transcription 3 (STAT3) (Muromoto et al., 2008).
STAT3 has drawn much attention due to its important role in
oncogenesis (reviewed in Yu et al. [2007]). It is shown that
ARL2 can enhance the interaction of BART with STAT3, and
overexpression of the T30N mutant ARL2 (defective in GTP
binding) blocks nuclear translocation of activated STAT3,
indicating that the ARL2-GTP-BART complex rather than BART
alone plays a role in modulation of STAT3 activity (Muromoto
et al., 2008). However, it remains unclear how BART participates
in these biological processes and what the underlying mecha-
nism is.
Here we report the crystal structure of human ARL2-GTP in
complex with BART. Analysis of the complex structure together
with mutagenesis and in vitro binding assays reveals a novel
recognition and binding mode of small GTPase with effector
and provides the molecular basis for the high specificity of
ARL2 for BART. These results may provide hints for further
studies of the functional role(s) of BART.
RESULTS AND DISCUSSION
Structure of the ARL2-GTP-BART Complex
The ARL2-BART complex was crystallized in two crystal forms
at two different conditions. Form I crystals belong to space
group P21 and can diffract X-ray to 2.25 A˚ resolution and form
II crystals belong to space group P212121 and can diffract
X-ray to 3.30 A˚ resolution (Table 1). Both structures were solved
using the molecular replacement (MR) method and contain one
ARL2 molecule bound with a GTP and a Mg2+ ion at the active
site and one BART molecule in the asymmetric unit (Figures
1A and 1B). The intrinsic GTPase activity of ARL2 is very low, 602–610, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 603
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Crystal Structure of Human ARL2-GTP-BART ComplexFigure 1. Structure of the ARL2-GTP-BART
Complex
(A) A stereo view of the ARL2-GTP-BART
complex. ARL2 is colored in yellow with the
N-terminal a helix in cyan and the switch I, switch
II, and inter-switch regions in magenta, orange,
and blue, respectively. The bound GTP is shown
with a ball-and-stick model and the Mg2+ ion in
a green sphere. BART is colored in green with
the secondary structures labeled.
(B) A stereo view of a representative difference
Fourier Fo-Fcmap (2s contour level) in the interac-
tion interface of the ARL2-BART complex in the
region of helix a1 of ARL2 and helix a4 of BART.
(C) Superposition of ARL2-GTP in the ARL2-GTP-
BART (red) and ARL2-GTP-PDEd complexes
(blue) and ARL3-GDP (yellow) showing the overall
conformational differences.
(D) Superposition of the crystal structure of BART
in the ARL2-GTP-BART complex (green) and the
NMR solution structure of BART alone (yellow)
showing the overall conformational differences.604 Structure 17, 602–610, April 15, 2009 ª2009 Elsevier Ltd All rights reserved
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(Clark et al., 1993), which might explain why ARL2 does not
hydrolyze GTP during the crystallization. The final structure
model in form I consists of ARL2 residues 2–184 followed by
residues LEHHHH of the C-terminal His tag, BART residues
19–102 and 105–134, a GTP, a Mg2+ ion, and 106 water mole-
cules. The N-terminal residues 1–18, residues 102–103, and
the C-terminal residues 135–163 of BART are undefined with
invisible electron density. Later SDS-PAGE analysis of the dis-
solved crystals of form I indicates that BART was degraded
with a molecular mass of 14 kDa in the complex. Further
biochemical data show that the BART truncate with omission
of the N terminus (D1–18) and the C terminus (D135–163) has
a comparable binding affinity to the wild-type protein, suggest-
ing that the N and C termini of BART are not essential for BART
binding with ARL2 (see discussion below). The average B factors
of BART are relatively higher than those of ARL2 (Table 1).
Crystal packing analysis indicates that although both ARL2
and BART are involved in crystal packing, ARL2 has more inter-
actions with symmetry-related molecules than BART (41 resi-
dues or 21.7% of ARL2 versus 16 residues or 14.0% of
BART). This may in part account for the relatively higher B
factors of BART. The final structure model in form II comprises
ARL2 residues 2–184 followed by residues LEHHHH of the
C-terminal His tag, BART residues 14–133, a GTP, a Mg2+ ion,
and 15 water molecules. The overall structures of both ARL2
and BART in the two crystal forms are almost identical (an
rmsd of 0.6 A˚ for ARL2 and 0.7 A˚ for BART) and there is no
notable difference at the ARL2-BART interface. Therefore, the
high-resolution structure of the ARL2-GTP-BART complex in
form I is used in further structural analysis and discussed below.
ARL2 in the complex assumes a typical small GTPase protein
fold consisting of a six-stranded b sheet surrounded by five
a helices with the N-terminal 12 residues forming an extra a helix
(Figures 1A and 1C; see Figure S1 available online). The overall
structure of ARL2 is very similar to that in the ARL2-PDEd
complex (Protein Data Bank [PDB] accession code 1KSG) with
an RMSD of 0.59 A˚ for 165 Ca atoms except that the N-terminal
a helix adopts a different conformation (Figure 1C). The switch
regions of ARL2 in this complex adopt similar conformations
as those in the ARL2-GTP-PDEd complex, which are character-
istic conformations for the GTP-bound small GTPases (Hanzal-
Bayer et al., 2002). Switch I (residues Asn37A-Phe50A; residues
of ARL2 will be designated by a superscripted suffix A and those
of BART by a superscripted suffix B hereafter) assumes a loop
conformation and is involved in the binding of GTP and Mg2+.
Switch II (residues Asp66A-Asn79A) forms a 310 helix (h1) and
residues of the conserved DXXGQ motif interact with the
g-phosphate of GTP. The inter-switch region (residues Asn51A-
Trp65A) forms two short b strands. The P loop (residues
Gly23A-Thr30A) is involved in the interactions with the phos-
phates of GTP. The bound GTP is buried in a closed binding
pocket and has extensive hydrophilic and hydrophobic interac-
tions with the surrounding residues. The bound Mg2+ ion has
six ligands in an octahedral geometry, including the side-chain
Og1 of Thr30A (2.3 A˚), the side-chain Og1 of Thr47A (2.2 A˚),
one b-phosphate oxygen (2.3 A˚) and one g-phosphate oxygen
(2.2 A˚) of GTP, and two water molecules (2.1 and 2.2 A˚, respec-
tively). Most of the interactions with GTP and Mg2+ areStructure 17,conserved in the ARL2-GTP-PDEd complex and other small
GTPase-GTP complexes.
As a characteristic feature of the ARF proteins, transformation
from the inactive GDP-bound state to the active GTP-bound
state is accompanied by substantial conformational changes
of the inter-switch region called ‘‘b sheet register shift’’ and
subsequent release of the N-terminal myristoylated a helix
(Amor et al., 1994; Goldberg, 1998; Greasley et al., 1995; Mene-
trey et al., 2000; Pasqualato et al., 2001). Like in the structures of
the ARL3-GDP (PDB accession code 1FZQ) and ARL2-GTP-
PDEd complexes (Hanzal-Bayer et al., 2002; Hillig et al., 2000),
a b sheet register shift of the inter-switch region of ARL2 is
also observed in this structure. Compared with the ARL3-GDP
structure, b strands b2 and b3 of the inter-switch region in this
complex slide by two residues relative to the remaining b sheet,
leading to the departure of the N terminus from the core of ARL2
and the change of its conformation from a one-turn a-helical coil
in ARL3-GDP to a three-turn a helix in ARL2-GTP. It is interesting
to observe that the N-terminal a helix of ARL2-GTP can adopt
two different conformations in its complexes with PDEd and
BART, suggesting that the N-terminal a helix and the following
loop of ARL2 have inherent flexibility in solution and the binding
of effector stabilizes their conformations.
BART consists of six a helices forming an a-helical bundle
(Figures 1A and 1D and Figure S2). The scaffold of BART is stabi-
lized by extensive hydrophobic interactions between a number
of aromatic residues, including 11 Phe residues and 3 Tyr
residues. Helices a3, a4, and a5 form a hydrophobic pocket to
accommodate the N-terminal helix a1 of ARL2 (see discussion
later). Recently, an NMR structure of human BART (PDB acces-
sion code 2K9A) was reported (Bailey et al., 2008). In addition, an
NMR structure of zebrafish BART was deposited with the PDB
(accession code 2K0S). The architecture of the crystal structure
of BART in complex with ARL2 is similar to that of the solution
structure of BART alone (Figure 1D). Nevertheless, there are
notable conformational differences in the orientations of several
a helices. Particularly, compared with the solution structure,
helix a4 in the complex structure makes an 30 rotation away
from helix a5 to create the hydrophobic cleft to accommodate
helix a1 of ARL2. This is in agreement with the suggestion that
the structure of BART has a ‘‘soft’’ architecture and the a helices
undergo reorientations upon the binding of ARL2 (Bailey et al.,
2008). In the titration experiments of BART with ARL2, a number
of residues exhibited substantial chemical shifts and thus were
suggested to be involved in interactions with ARL2, including
helix a2 (Asp30B, Met33B, Asp35B, and Gln38B), the a2-a3
loop (Thr55B and Asn58B), the a3-a4 loop (Gln83B, Gly87B, and
Asn89B), and the a4-a5 loop (His99B and Asp102B). In the
ARL2-BART complex, only Asn58B is directly involved in the
interaction with ARL2. Most of the other residues are located
on the loops and their conformational changes upon the ARL2
binding are due to rearrangement of the overall structure instead
of direct involvement in the interaction. The architecture of the
zebrafish BART structure is substantially different from that of
the human BART structures. This may be due to the difference
of species and/or the relatively low resolution of the zebrafish
BART structure (Bailey et al., 2008). Sequence comparison
shows that BART is highly conserved in different species,
suggesting that it should have a conserved structure (Figure S2).602–610, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 605
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The interactions between ARL2-GTP and BART involve two
interfaces and bury 2281 A˚2 or 12.5% of the total solvent-acces-
sible surface area of the complex (Figure 1A). Interface I involves
extensive hydrophobic interactions between the N-terminal
a helix of ARL2 and the hydrophobic pocket formed by helices
a3, a4, and a5 of BART (Figures 2A and 2C). In particular, helix
a1 of ARL2 parallels helix a4 of BART, and the hydrophobic
residues of a well-conserved sequence motif LLXIL (Leu3A,
Leu4A, Ile6A, and Leu7A) of helix a1 of ARL2 make extensive
hydrophobic contacts with several hydrophobic residues of
BART, including Val73B, Ile77B, Met90B, Phe93B, Leu97B,
Phe109B, Leu112B, Leu113B, and Phe115B. In addition, several
hydrogen bonds are formed at this interface (Figure 2D). The
main-chain amino of Leu3A forms a hydrogen bond with the
side-chain O31 of Glu74B (2.4 A˚). The side-chain Nz of Lys8A
forms a hydrogen bond with the main-chain carbonyl of
Thr116B (3.4 A˚). The side-chain Nz of Lys11A forms hydrogen
bonds with the main-chain carbonyl of Phe109B (2.7 A˚) and the
side-chain Od2 of Asp110B (3.4 A˚). These interactions stabilize
the conformation of the N-terminal a helix of ARL2.
Interface II involves both hydrophobic and hydrophilic inter-
actions between the switch regions (primarily switch I) of ARL2
and the N terminus of helix a3 and the following loop of BART
(Figures 2B–2D). In particular, a network of hydrogen-bonding
interactions predominate this interface. Specifically, the side-
chain O31 of Glu56B of BART forms a salt bridge with the side-
chain Nz atom of Lys34A (2.9 A˚) of ARL2. The side-chain O32
of Glu57B forms two hydrogen bonds with the main-chain amino
groups of Leu48A (3.0 A˚) and Gly49A (3.1 A˚). The main-chain
carbonyl of Asn58B forms a hydrogen bond with the main-chain
amino of Phe50A (2.9 A˚), and the main-chain amino and side-
chain Nd2 of Asn58B form two hydrogen bonds with the main-
chain carbonyl of Phe50A (2.8 and 3.3 A˚, respectively). The
main-chain carbonyl of Leu60B and side-chain Og1 of Thr63B
form a hydrogen bond each with the side-chain Oh of Tyr80A
(3.5 and 2.8 A˚, respectively).
To confirm the interactions and further investigate the roles of
the residues at the interfaces, we performed site-directed
mutagenesis studies and in vitro GST pull-down assays. We first
examined the effects of mutations of the N-terminal LLXIL motif
Figure 2. Interactions between ARL2-GTP and BART
(A) A stereo view showing the interactions between ARL2 and BART at
interface I. Helix a1 of ARL2 (cyan) is embedded in a hydrophobic cleft formed
by helices a3, a4, and a5 of BART (green).
(B) A stereo view showing the interactions between ARL2 and BART at
interface II. The switch regions of ARL2 (switches I and II and the inter-switch
region in magenta, orange, and blue, respectively) have both hydrophobic and
hydrophilic interactionswith the N terminus of helix a3 and the following loop of
BART (green). The hydrogen-bonding interactions are indicated by dashed
lines.
(C) A schematic diagram showing the hydrophobic contacts between ARL2
and BART.
(D) A schematic diagram showing the hydrogen-bonding interactions between
ARL2 and BART.
(E) In vitro binding assay of the wild-type and mutant ARL2 with the GST-fused
wild-type BART. GST cannot bind to ARL2 and thus was used as the negative
control.
(F) In vitro binding assay of the wild-type ARL2 with the GST-fused wild-type
and mutant BART.ts reserved
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Crystal Structure of Human ARL2-GTP-BART ComplexFigure 3. Comparison of the Recognition
and Binding Mode of ARL2 with BART
in the ARL2-GTP-BART Complex with that
of ARL2 with PDEd in the ARL2-GTP-PDEd
Complex
The structure of humanRAP1A in complexwith the
RAS-binding domain of c-RAF1 is also included
for comparison (Nassar et al., 1995).of ARL2 at interface I on the binding of ARL2 with BART
(Figure 2E). The biochemical data show that deletion of residues
2–4 of ARL2 abolishes its bindingwith BART.Mutation L3D, L4D,
or L7D alone can disrupt the binding of ARL2with BART because
introduction of a charged side chain destabilizes the hydro-
phobic contacts with BART. Mutation L3A impairs the binding
of ARL2 with BART due to loss of the extensive hydrophobic
contacts with BART. Mutations L4A and L7A show no notable
effect on the binding affinity probably due to their moderate
hydrophobic contacts with BART. In vitro binding assay shows
that ARL2 and ARL3 can bind BART whereas ARL6 cannot
(data not shown). Sequence analysis indicates that ARL2,
ARL3, and ARL6 contain the three conserved Leu residues at
the N terminus, but ARL2 and ARL3 have a conserved Ile at posi-
tion 6 whereas ARL6 has an Arg at the equivalent position
(Figure S1). Mutation of Ile6A to Arg in ARL2 abrogates its binding
with BART, suggesting that Arg6 of ARL6 may account for its
inability to bind BART (Figure 2E).
We then investigated the effects of mutations of several
residues of BART at interface I on its binding with ARL2
(Figure 2F). Residues Phe109B, Leu112B, and Phe115B of
BART have several van der Waals contacts with the LLXIL motif
of ARL2. Mutations of these residues to Ala decrease its binding
with ARL2. The side chain of Asp110B forms a hydrogen bond
with Lys11A of ARL2 and replacement of Asp110B with Ala also
resulted in weakened binding. The side chain of Glu74B forms
a hydrogen bond with the main-chain amide of Leu3A of ARL2
and van der Waals contacts with both Leu3A and Leu4A of
ARL2. Mutation of Glu74B to Ala causes a decreased binding
with ARL2. Residue Met111B is not involved in the interactions
and therefore was chosen to serve as a negative control. As
expected, mutation of Met111B to Ala shows no notable effect
on the binding. These results further underline the importance
of the hydrophobic interactions between the LLXIL motif of
ARL2 and BART at interface I in the ARL2-BART binding and
suggest a more important role of Leu3A of ARL2 than Leu4A
and Leu7A in the binding with BART.
At interface II several residues of both ARL2 and BART were
also mutated to examine their effects on the binding of ARL2
with BART (Figures 2E and 2F). On the side of ARL2, the main
chain of Phe50A forms three hydrogen bonds with Asn58B of
BART and the side chain makes hydrophobic contacts with
several residues of BART. Mutation of Phe50A to Ala does not
affect the hydrophilic interactions but abrogates the hydro-
phobic contact and therefore diminishes the binding of ARL2
with BART. The side chain of Tyr80 A forms two hydrogen bonds
with BART and mutation of Tyr80 A to Ala causes a decrease inStructure 17the binding with BART. Residue Tyr76 A is not directly involved
in interaction with BART and hence itsmutation to Ala (as a nega-
tive control) has no notable effect on the binding. On the side of
BART, mutation of Glu56B to Ala leads to a decrease in the
binding with ARL2 due to loss of the salt-bridge interaction
with Lys34A. The mutant E57A shows a weaker binding with
ARL2 because of loss of the hydrogen-bonding interactions
with the switch I of ARL2. Mutation of Leu60B to Ala leads to
a decrease in the binding with ARL2 due to loss of the extensive
hydrophobic contacts with the switch regions of ARL2. Because
the N-terminal residues 1–18 and the C-terminal residues 135–
163 of BART are undefined in the structure, we also performed
in vitro binding assay of the corresponding BART truncate
(residues 19–134 and the result shows that deletion of residues
1–18 and 135–163 of BART has no notable effect on the binding
with ARL2 (Figure 2F), indicating that the observed interactions in
the complex include most if not all interactions between ARL2
and BART. Together, the structural and biochemical data
demonstrate that both interfaces are essential in the binding of
ARL2 with BART.
A Novel Recognition and Binding Mode between ARL2
and BART
Structural comparison indicates that the recognition and binding
of ARL2 with BART via both the N-terminal a helix and the switch
regions is different from that of ARL2 with PDEd (Figure 3). In the
ARL2-GTP-PDEd complex, the protein-protein interactions
involve primarily b2 of the inter-switch region of ARL2 and b7
of PDEd, forming a ten-stranded inter-protein b sheet (Hanzal-
Bayer et al., 2002). Additionally, switches I and II of ARL2 also
make hydrophobic and hydrophilic interactions with b1, b4, b6,
and the b6/b7 turn of PDEd to enhance the specificity of ARL2
for PDEd. However, the N-terminal a helix of ARL2 protrudes
on the surface and has no interaction with either the core of
ARL2 or PDEd. In contrast, in the ARL2-GTP-BART complex,
the interactions between the switch regions of ARL2 and BART
involve much fewer residues and thus are much weaker than
those in the ARL2-GTP-PDEd complex. As compensation, the
N-terminal a helix of ARL2 participates in the recognition and
binding to increase its specificity for BART.
On the other hand, structural analysis indicates that the
residues of the switch regions of ARL2 that have direct interac-
tions with BART (Lys34A, Leu48A, Gly49A, Phe50A, and Tyr80A)
also participate in the interactions with PDEd and are strictly
conserved (except Leu48A, which is highly conserved) in all
ARL2, ARL3, and ARL6 orthologs (Figure S1). Thus, it seems
possible that these residues of ARL2, ARL3, and ARL6 are also, 602–610, April 15, 2009 ª2009 Elsevier Ltd All rights reserved 607
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and biochemical results also show that the N-terminal a helix of
ARL2 contains an LLXIL motif that plays an important role in its
binding with BART. Sequence alignment of the small GTPases
shows that only ARL2 and ARL3 contain this LLXIL motif at the
N terminus. This might explain why only ARL2 and ARL3 in the
ARL proteins have the ability to bind BART. It is very likely
that ARL3 would recognize and bind BART in the same mode
as that of ARL2.
Formost of the small GTPases, such as RAS, RAP, RHO, RAC,
and RAB, the recognition and binding with the effectors involve
conformational changes of largely the switch I and II regions
and the differences in primary sequences and structures of these
regions determine the specificity with their effectors (Vetter and
Wittinghofer, 2001). The recognition and binding of some other
small GTPases with the effectors involve conformational
changes of extra structural elements in addition to the switch I
and II regions. During the GDP-GTP exchange, RAN displays
large conformational changes of both switch I and the C-terminal
region (the C-terminal switch) (Vetter et al., 1999a, 1999b; Chook
and Blobel, 1999). For ARF and ARL proteins, the GDP-GTP
exchange is accompanied by the conformational changes of
the inter-switch region (the b-register shift) and the N-terminal
region (the N-terminal switch) (Antonny et al., 1997; Goldberg,
1998; Hanzal-Bayer et al., 2002; Hillig et al., 2000). The recogni-
tion and binding mode of ARL2 with BART also involves confor-
mational changes of both the switch regions and the N-terminal
a helix. In particular, it is the first time to observe that the
N-terminal switch of a small GTPase is directly involved in the
recognition and binding of its effector. This is different from
the recognition and binding mode of the other small GTPases
with their effectors, including ARL2 with its effector PDEd
(Figure 3).
In contrast to members of other families within the small
GTPase superfamily, the N terminus of the ARF family members
plays important but distinct functional roles. The N terminus of
the ARF proteins undergoes conformational change during the
GDP-GTP exchange and serves as the membrane anchor
through myristoylation and interaction with membrane lipids
(Goldberg, 1998; Kahn et al., 1995; Pasqualato et al., 2002).
The N terminus of ARL3 is involved in its targeting to the Golgi
through acetylation and interaction with membrane proteins
(Behnia et al., 2004; Setty et al., 2004). Although the N terminus
of ARL2 is not myristoylated or acetylated, it undergoes confor-
mational change during the GDP-GTP exchange and sometimes
is involved in the recognition and binding with the effector (such
as BART) and other times is not (such as PDEd) (Hanzal-Bayer
et al., 2002). These findings will aid our understanding of the
specificity of the small GTPase signaling pathways and will
provide important clues to the biological functions of the ARL
proteins and the other small GTPases in general.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Proteins
The cDNA of full-length ARL2 was amplified from the cDNA library of human
CD34+ hematopoietic stem/progenitor cells (Zhang et al., 2000) and inserted
into the NdeI and XhoI restriction sites of the pET-22b(+) expression plasmid
(Novagen), which attaches a 63-His tag at the C terminus of the target protein.
The plasmid was transformed into Escherichia coli BL21 (DE3) strain. The608 Structure 17, 602–610, April 15, 2009 ª2009 Elsevier Ltd All rightransformed cells were grown in LBmedia at 37C containing 0.1 mg/ml ampi-
cillin until OD600 reached 0.8, and then induced with 0.5 mM IPTG for 10 hr at
20C. The cells were harvested and lysed by sonication in a lysis buffer (buffer
A) containing 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM b-mercaptoetha-
nol, 2 mM MgCl2, and 1 mM GTP. The target protein ARL2 was purified by
affinity chromatography using a Ni-NTA column (Amersham) with buffer A
supplemented with 30 and 200 mM imidazole serving as washing buffer and
elution buffer, respectively.
The cDNA of full-length BART was also amplified from the cDNA library of
human CD34+ hematopoietic stem/progenitor cells and inserted into the
BamHI and XhoI restriction sites of pGEX-4T-1 plasmid (Amersham), which
attaches a GST tag at the N terminus of the target protein. The plasmid was
transformed into E. coli BL21 (DE3) strain and the bacteria were induced as
described above. The harvested cells were lysed by sonication in buffer B
(30 mM Tris-HCl [pH 7.5], 100 mM NaCl, 2 mM MgCl2, and 2 mM DTT) and
the supernatant was loaded onto a glutathione Sepharose 4B column (Amer-
sham). The resin was first washed with buffer B and then the excessive amount
of the purified ARL2 (about 1.5:1 molar ratio) was loaded onto the column to
obtain the ARL2-BART complex. After further washing with buffer A, thrombin
(Sigma) cleavage was performed on the column for 10 hr at 4C. The released
ARL2-BART complex was concentrated to about 16 mg/ml, and then frozen in
liquid nitrogen and stored at80C in buffer A for structural study. The purity of
the complex was more than 95% as revealed by SDS-PAGE and gel filtration
analyses. Because excessive ARL2 was loaded onto the BART-GST beads
and the binding affinity between ARL2 and BART is very high (apparent KD
of 20 nM) (Sharer and Kahn, 1999), no notable BART and ARL2 were found
to exist in free form. The concentration of the proteins was measured using
the Protein Assay Kit (Bio-Rad) following the instruction manual.
Constructs of the mutant ARL2 and BART containing point mutations were
generated using the QuikChange Site-Directed Mutagenesis Kit (Strategene)
following the instruction manual. Expression plasmid of the N terminus-
truncated ARL2 was generated using the same method as the full-length
ARL2. Expression plasmids of the N and C terminus-truncated BART were
generated using the same method as the full-length BART. All of these clones
were verified by DNA sequencing. The mutant ARL2 and BART proteins were
expressed and purified with similar procedures except that the BART protein
alone was stored in buffer B.
Crystallization, Data Collection, and Structure Determination
Crystallization of the ARL2-BART complex was performed using the hanging
drop vapor diffusion method by mixing 1.5 ml of protein solution (about
16mg/ml of the complex) and 1.5 ml of reservoir solution. Two forms of crystals
of the ARL2-BART complex were obtained after about 4 weeks. Form I crystals
were grown from drops consisting of a reservoir solution of 0.1 M bicine
(pH 9.0), 10% PEG 6000, and 20 mM hexammine cobalt (III) chloride at 4C
that belong to space group P21 and a native data set of 2.25 A˚ resolution
was collected at beamline BL-5A of Photon Factory. Form II crystals were
grown from drops consisting of a reservoir solution of 0.2 M MgCl2 (pH 5.9)
and 20% PEG 3350 at 20C that belong to space group P212121 and a native
data set of 3.30 A˚ resolution was collected at beamline BL-6A of Photon
Factory. Both data sets were collected from flash-cooled crystals at 100 K
and processed with HKL2000 (Otwinowski and Minor, 1997). The statistics
of the diffraction data are summarized in Table 1.
The structure of the ARL2-BART complex in form I was solved using the MR
method as implemented in the program CNS (Brunger et al., 1998) with the
structure of murine ARL2 (PDB accession code 1KSG) as the search model.
In the initial MR-phased electron-density map the ARL2 structure is well
defined. In addition, there was very good electron density for a GTP molecule
and a metal ion at the active site of ARL2. However, the MR-phased map only
showed clear but discontinuous electron density for several a helices of BART.
Iterative cycles of model building of a partial polyalanine model with the
electron density and subsequent real-space refinement gradually developed
new and continuous electron density and allowed further building of a full
BART model (Figure 1B). Because this diffraction data set was collected at
a high wavelength (l = 1.5596 A˚) with sufficient redundancy (average of 6.6),
we reprocessed it to split the anomalous contributions. Single-wavelength
anomalous diffraction phasing using SOLVE did not reveal outstanding peaks
for the sulfur atoms probably due to their weak signals. However, MR phasingts reserved
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structure reveals evident anomalous difference peaks (above 2s level) for
the sulfur atoms of all Met and Cys residues (Met10, Met21, Met99, Cys102,
Cys153, and Cys157 of ARL2 and Met33, Met45, Met90, and Met124 of
BART) except Met111 of BART (which might have a higher flexibility than
others). A representative of an anomalous difference Fourier map (2.0s level)
in the interaction interface region of helix a1 of ARL2 (Met10) and helix a4 of
BART (Met90) is shown in Figure S3. These results further validate the reliability
and correctness of the complex structure. The structure of the ARL2-BART
complex in form II was solved using the MR method with the structure of the
ARL2-GTP-BART complex in form I as the search model. Structure refinement
was carried out using programsCNS and REFMAC5 (TLS and hydrogen atoms
were not used in the refinement) (Murshudov et al., 1997) and model building
using programs O (Jones et al., 1991) and Coot (Emsley and Cowtan, 2004).
The stereochemistry of the protein models was analyzed using programs
PROCHECK (Laskowski et al., 1993) and MolProbity (Davis et al., 2007). The
statistics of the structure refinement and the final structural model are summa-
rized in Table 1.
In Vitro GST Pull-Down Assay
To investigate the effects of mutations of the residues involved in the
ARL2-BART interaction, we performed in vitro protein-protein binding assay.
The purified ARL2 proteins were first exchanged into a buffer (30 mM Tris-HCl
[pH 7.5], 100 mMNaCl, and 2 mMDTT) containing 10 mMEDTA to remove the
prebound metal ion and nucleotides (nucleotide-free form) and then dialyzed
into a buffer (30 mM Tris-HCl [pH 7.5], 100 mM NaCl, 2 mM MgCl2, and
2 mM DTT) containing 10 mM GTP (about 100-fold excess of GTP over the
protein) (GTP-bound form). Such prepared ARL2 proteins were confirmed to
be in the GTP-bound form (Figure S4). Approximately 20 mg of the GST-fused
wild-type or mutant BART protein was immobilized onto the glutathione
Sepharose beads and then incubated with 60 mg of the GTP-bound wild-
type ormutant ARL2 protein for 2 hr at 4C. Themixture waswashed four times
with washing buffer (30 mM Tris-HCl [pH 7.5], 500 mM NaCl, 2 mM MgCl2,
0.5% Nonidet P-40, 1 mM GTP, and 2 mM DTT). The beads were then boiled
with the SDS-sample buffer and the proteins were analyzed by SDS-PAGE
with Coomassie blue staining. Binding assay with the GST protein alone was
used as a negative control.
ACCESSION NUMBERS
The atomic coordinates and structure factors of the ARL2-GTP-BART
complex in crystal forms I and II have been deposited with the Research
Collaboratory for Structural Bioinformatics Protein Data Bank with accession
codes 3DOE and 3DOF, respectively.
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